The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis

Xue, Song; Song, Ge; Yu, Jinming

doi:10.1038/s41598-017-04023-x

Cited by 63 publications

(52 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some could argue that the tumors in the refractory Bev group were the recurrent tumors following not only Bev but also radiotherapy and temozolomide, and those therapies might also have affected the immunohistochemical results. However, the expression of PD-1 and PD-L1 was known to increase in recurrent glioblastomas, 16,29 and the results contrary to those were very likely due to the effect of Bev.…”

Section: Limitations Of the Studymentioning

confidence: 71%

“…Programmed cell death ligand‐1 is frequently expressed in glioblastomas reportedly in 61%‐88% of tumor cells . Previous studies showed that high PD‐L1 expression correlated with worse OS in patients with glioblastoma . The expression of PD‐L1 is induced by various pro‐inflammatory molecules such as γ‐interferon and VEGF‐A in the tumor microenvironment .…”

Section: Discussionmentioning

confidence: 99%

“…15 Previous studies showed that high PD-L1 expression correlated with worse OS in patients with glioblastoma. 16 The expression of PD-L1 is induced by various pro-inflammatory molecules such as γ-interferon and VEGF-A in the tumor microenvironment. 17,18 However, to date, no study has reported the change in PD-L1 expression under antiangiogenic therapy.…”

Section: Programmed Cell Death Ligand-1/pd-1/cd3/ Cd8/tregsmentioning

confidence: 99%

See 2 more Smart Citations

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab

et al. 2018

View full text Add to dashboard Cite

Although vascular endothelial growth factor (VEGF) promotes the immunosuppressive microenvironment, the efficacy of bevacizumab (Bev) on tumor immunity has not been fully investigated. The present study used 47 glioblastoma tissues obtained at 3 different settings: tumors of initial resection (naïve Bev group), tumors resected following Bev therapy (effective Bev group), and recurrent tumors after Bev therapy (refractory Bev group). The paired samples of the initial and post‐Bev recurrent tumors from 9 patients were included. The expression of programmed cell death‐1 (PD‐1)/PD ligand‐1 (PD‐L1), CD3, CD8, Foxp3, and CD163 was analyzed by immunohistochemistry. The PD‐L1+ tumor cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P < .01 for each). The PD‐1+ cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P < .01 for each). The amount of CD3+ and CD8+ T cell infiltration increased in the refractory Bev group compared with the naïve Bev group (CD3, P < .01; CD8, P = .06). Both Foxp3+ regulatory T cells and CD163+ tumor‐associated macrophages significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (Foxp3, P < .01 for each; CD163, P < .01 for each). These findings were largely confirmed by comparing paired initial and post‐Bev recurrent tumors. Bevacizumab restores the immunosupportive tumor microenvironment in glioblastomas, and this effect persists during long‐term Bev therapy.

show abstract

Section: Limitations Of the Studymentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Section: Programmed Cell Death Ligand-1/pd-1/cd3/ Cd8/tregsmentioning

confidence: 99%

See 1 more Smart Citation

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, related research has reported the significance of PD-L1 expression on tumour tissues as an independent poor prognostic factor [57,58]. In this paper, we have investigated the clinical relevance of immune system biomarkers, TILs, TAMs, TBs, and PD-L1, in MIBC patient prognosis.…”

Section: Discussionmentioning

confidence: 98%

Identification of Immunological Features Enables Survival Prediction of Muscle-Invasive Bladder Cancer Patients Using Machine Learning

Gavriel

Dimitriou

Brieu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Clinical staging and prognosis of muscle-invasive bladder cancer (MIBC) routinely includes assessment of patient tissue samples by a pathologist. Recent studies corroborate the importance of image analysis in identifying and quantifying immunological markers from tissue samples that can provide further insights into patient prognosis. In this paper, we apply multiplex immunofluorescence on MIBC tissue sections to capture whole slide images and quantify potential prognostic markers related to lymphocytes, macrophages, tumour buds, and PD-L1. We propose a machine learning based approach for the prediction of 5 year prognosis with different combinations of image, clinical, and spatial features. An ensemble model comprising several functionally different models successfully stratifies MIBC patients into two risk groups with high statistical significance (p value < 1e − 05). Critical to improving MIBC survival rates, our method classifies correctly 71.4% of the patients who succumb to MIBC within 5 years, significantly higher than the 28.6% of the current clinical gold standard, the TNM staging system.

show abstract

“…15,16 Importantly, PD-L1 and PD-L2 expression correlated with poor prognosis in different tumor types, including breast cancer, urothelial cancer, renal cancer, gastric cancer, melanoma, glioma, ovarian cancer, and lung cancer. [17][18][19][20] Tumor heterogeneity can present an additional mechanism of tumor cell escape from CAR T-cell therapies, as not all cells of a tumor might express sufficient levels of the targeted antigen to be recognized and eliminated by the CAR T cells. This phenomenon is called ''antigen loss,'' and relapses due to antigen loss may be prevented by simultaneously targeting two tumor antigens.…”

mentioning

confidence: 99%

Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors

Morgan

Schambach

2018

Human Gene Therapy

View full text Add to dashboard Cite

Successful translation of chimeric antigen receptor (CAR) T cells designed to target and eradicate CD19+ lymphomas has emboldened scientists and physicians worldwide to explore the possibility of applying CAR T-cell technology to other tumor entities, including solid tumors. Next-generation strategies such as fourth-generation CARs (CAR T cells redirected for universal cytokine killing, also known as TRUCKs) designed to deliver immunomodulatory cytokines to the tumor microenvironment, dual CAR designs to improve tumor control, inclusion of suicide genes as safety switches, and precision genome editing are currently being investigated. One major ongoing goal is to determine how best to generate CAR T cells that modulate the tumor microenvironment, overcome tumor survival mechanisms, and thus allow broader applicability as universal allogeneic T-cell therapeutics. Development of state-of-the-art and beyond viral vector systems to deliver designer CARs coupled with targeted genome editing is expected to generate more effective off-the-shelf CAR T cells with activity against a greater number of cancer types and importantly solid tumors.

show abstract

The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis

Cited by 63 publications

References 21 publications

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab

Identification of Immunological Features Enables Survival Prediction of Muscle-Invasive Bladder Cancer Patients Using Machine Learning

Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors

Contact Info

Product

Resources

About